SI
SI
discoversearch

Biotech / Medical
Trillium Therapeutics
An SI Board Since February 2014
Posts SubjectMarks Bans Symbol
153 51 0 TRIL
Emcee:  tuck Type:  Unmoderated
The following is how Trillium now thinks of itself as of 8/31/2017:

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available epidermal growth factor receptor antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

The board logo is CD47 in complex with SIRP, the pathway targeted by the lead program.

Website: Trillium Therapeutics
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
153THIS is why they have that tacky F-10 out there. If investors/traders can make scaram(o)uche-Wednesday
152The company also announced that Eric Sievers, MD, has transitioned from Chief Mescaram(o)uche1Wednesday
151"These additions to our management team further bolsters our planned pipeliscaram(o)uche-Wednesday
150Thank you! Be nice if they published it. Be nice if it was included in datascaram(o)uche-Tuesday
149I actually asked the company about SLAMF7 last May. They responded that they hadBiomaven-Tuesday
148Unfortunately, I can't see the figures with sufficient resolution to learn mscaram(o)uche-Sunday
147(Published online: January 11, 2018) Accumulating data suggest that SIRPa–CD47 scaram(o)uche1Sunday
146Mr. James Parsons Chief Financial Officer Mr. Parsons is responsible for financscaram(o)uche-last Friday
145When your Business Development team is occupied with revising the header to a S.scaram(o)uche-last Friday
144Maybe next decade (or next century, whatever) someone will turn eyes on them (TRMiljenko Zuanic-last Friday
143I think (but I'm not 100% sure) that the 11/17/17 date in the PR about the MDewDiligence_on_SI-January 11
142fortyseveninc.com Forty Seven Inc. to Collaborate on a Novel Immuno-Oncology Coscaram(o)uche-January 11
141Making money the old-fashioned way....... form EFFECT out, here's the proscaram(o)uche-January 9
140Maybe I am mistaking, but seams to me that TTI-621 has small chances (except iMiljenko Zuanic-January 4
139I actually added a bit today too. I tend to hold long term and just wanted to bughmm-January 4
138I thought the data presented at ASH were pretty good. I thought the Market reaBladerunner17-January 4
137I do not think there is need to rush to increase TRIL position! Do you have strMiljenko Zuanic1January 4
136Bought more TRIL this morning at $7.68. Anyone else buying on the dips? BladeBladerunner17-January 4
135Losing competitive advantage, every single day. Parsons scared crapless that, iscaram(o)uche-12/21/2017
134And let's not forget the perfect pairing for FREE warrants..... cheap opscaram(o)uche-12/18/2017
133I'm going with c) myself. That, in combo with tax loss selling, is juicing tuck-12/18/2017
132>> or/and few bitcoins do do P1-finance << Yeah. And yet the poorlscaram(o)uche-12/18/2017
131Good to hear from you! Figured you had gone searching for sunsets and hammocks.scaram(o)uche-12/18/2017
130Could just be Y/E selling by a fund. TRIL is relatively illiquid. Fund may prIan@SI-12/18/2017
129Well, I am not sure about? It only take few once of gold or/and few bitcoins do Miljenko Zuanic-12/18/2017
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.